secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2022-10-24T23:59:59+00:00
Accession:  0001628280-22-026904
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

GSK terminates collaboration with Lyell; NY-ESO-1 programs discontinued
-----------------------------------------------------------------------

- GSK provided termination notice Oct 24, 2022, effective Dec 24, 2022; ends development of LYL132 and LYL331 incorporating Lyell's technologies.
- Termination follows GSK's strategic review after lete-cel NSCLC data; not based on safety/efficacy of Lyell's programs.
- Lyell discontinuing further work on these programs; minimal operational impact as GSK ran them; no patients treated with LYL132.
- Cash, cash equivalents and marketable securities expected to fund working capital into 2025; Glaxo Group remains significant stockholder.
- Lyell received $250M upfront/equity in 2019 collaboration; would have been eligible for milestones and royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828022026904/0001628280-22-026904-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828022026904/lyel-20221024.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-026904

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer